Dexpramipexole ((R)-Pramipexole) is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole upregulates the expression of Parkin, PINK1, GPX4 and FSP1, binds to mitochondrial F1/Fo-ATP synthase, blocks the Nav1.8 sodium channel, and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis, maintains mitochondrial function and redox homeostasis, reduces reactive oxygen species production, and decreases myocardial infarct size. Dexpramipexole is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more[1][2][3][4][5][6].
Molekulargewicht:
211.33
Reinheit:
99.56
CAS Nummer:
[104632-28-2]
Formel:
C10H17N3S
Target-Kategorie:
Apoptosis,ATP Synthase,Autophagy,Ferroptosis,Glutathione Peroxidase,Mitophagy,NOD-like Receptor (NLR),PINK1/Parkin,Reactive Oxygen Species (ROS),Sodium Channel
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
